Skip to main content

Table 3 Skin infections in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy

From: Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

   Time to event       
Infection No. of events Median Range Druga (no.) Active treatmentb (no.) Rechallenge (no.) Permanent withdrawal of anti-TNF-αc (no.) Biopsy (no.) Cultured species
Fungal 20 8.7 1.1–61.1       
   Dermatomycosis 9    A 3, I 4, E 2 7   0 1 Trichophyton verrucosum (1) T. rubrum (1)
   Onychomycosis 3    A 3 3   0 0  
   Combination 5    A 3, I 1, L 1 4   0 1 Trichophyton rubrum (3) T. mentagrofytes (1)
   Candidiasis 3    I 3 2   0 0 Candida spp. (2)
Bacterial 11 9.5 1.4–52.5       
   Folliculitis 5    A 3, E 2 4 yes, negative 1 2 Staphylococcus aureus (1)
   Erysipelas 3    E 2, I 1 3 yes, negative 2 1  
   Bacterial superinfection of eczema 2    A 1, I 1 1 yes, positive 1 0  
   Furuncle 1    I 1 0   0 0  
Viral – herpes zoster 2 17.3, 40.9d   A 1, I 1 0   0 0  
  1. aA, adalimumab; I, infliximab; E, etanercept; L, lenercept. bDuring active treatment with TNF-α-blocking therapy. cPermanent discontinuation of TNF-α-blocking therapy due to the event.d Individual values